TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$345 Million

Adaptive Biotechnologies Corp.

Initial Public Offering

Passive Bookrunner, June 2019

Adaptive Biotechnologies Corp.
Adaptive Biotechnologies Corporation is advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. The Company’s immune medicine platform applies its proprietary technologies to read the diverse genetic code of a patient’s immune system and understand precisely how it detects and treats disease in that patient. Adaptive captures these insights in its dynamic clinical immunomics database, which is underpinned by computational biology and machine learning, and uses them to develop and commercialize clinical products tailored to each individual patient. The Company’s products and services are designed to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases.